DAX-0,01 % EUR/USD+0,09 % Gold-0,12 % Öl (Brent)-0,85 %

Ist URIGEN PHARMA INC schon tot?


AnzeigeAdvertisement

Beitrag schreiben

Begriffe und/oder Benutzer

 

Antwort auf Beitrag Nr.: 39.374.491 von dagobernie am 21.04.10 12:58:27hallo dagobernie,

ich habe meine anteile die letzten monaten aufgestockt.
denke aber das es noch eine zeit ( 1-3 Jahre) dauern wird
bis richtig schwung reinkommt.

ciao zapal
Antwort auf Beitrag Nr.: 39.380.080 von Zapal am 22.04.10 07:18:25...und ich hab schon befürchtet ich wär der einzige der da dran glaubt.
bin seit 2007 dabei, habe grundsätzlich ein gutes gefühl mittelfristig .

23.04.2010 15:26
Urigen Files Request for FDA Meeting
Urigen Pharmaceuticals, Inc. (OTCBB:URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that it has filed a request for an FDA meeting to advance the URG101 clinical program and mutually agreed with Oceana Therapeutics, Inc. to terminate their Consulting Agreement effective immediately.

"Urigen's request to meet with the US Food and Drug Administration was filed yesterday. We look forward to working with the FDA as we move our URG101 program forward for Painful Bladder Syndrome/Interstitial Cystitis," said William J. Garner, MD, CEO.

"Ending our contractual obligation to Oceana enables us to pursue several additional commercial opportunities in the US and the EU more aggressively," stated, Edward R. Teitel, MD, JD, Chairman of Urigen.

Prof. Lowell Parsons, MD said, "After 30 years, in my opinion, from my clinical experience with URG101, it is the most significant advance in treating interstitial cystitis/painful bladder syndrome that has yet been developed and will greatly improve the quality of patients' lives."

URG101 is a patent-protected, regional therapy for Painful Bladder Syndrome/Interstitial Cystitis which afflicts millions of women and men. Urigen has previously announced positive results from a Phase 2 study of URG101. The study was a multi-center, double-blind, placebo-controlled, crossover trial. Findings from the study included: Primary Endpoint - Improvement in Average Daytime Pain (p=0.03). Secondary Endpoints - Improvement in Daytime Urgency (p=0.03) and Total Symptom Score (p=0.03). In addition, patients reported improved symptom relief with URG101 as measured by PORIS (p=0.01).

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. Urigen's URG301, a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. For further information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Urigen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urigen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Urigen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.



Contacts:

Urigen Pharmaceuticals, Inc.
William J. Garner, MD, 415-781-0350
Chief Executive Officer
http://www.urigen.com



© 2010 Business Wire
2010.04.23 15.26
Urigen Files Request for FDA Meeting
Urigen Pharmaceuticals, Inc. (OTCBB: URGP), ein spezialisiertes Pharmaunternehmen, das auf die Entwicklung von Behandlungen für urologische Erkrankungen und Schmerzen konzentriert, hat heute die einen Antrag auf eine Sitzung der FDA URG101 klinische Programm voraus und sich gegenseitig mit Oceana vereinbarten eingereicht Therapeutics, Inc., ihre Consulting Abkommen mit sofortiger Wirkung kündigen.

"Urigen Antrag mit der US Food and Drug Administration gerecht eingereicht wurde gestern. Wir freuen uns, mit der FDA zusammenzuarbeiten, da wir unsere URG101 Programm weiter für schmerzhafte Blase / interstitielle Zystitis zu bewegen", sagte William J. Garner, MD, CEO.

"Ending unsere vertragliche Verpflichtung zur Oceana ermöglicht es uns, einige zusätzliche Marktchancen in den USA und der EU mehr aggressiv verfolgen", sagte Edward R. Teitel, MD, JD, Vorsitzender des Urigen.

Prof. Lowell Parsons, MD, sagte: "Nach 30 Jahren, meiner Meinung nach, aus meiner klinischen Erfahrung mit URG101 es die bedeutendste Fortschritt in der Behandlung von interstitiellen Zystitis / schmerzhafte Blase-Syndrom, dass bisher noch entwickelt und verbessert deutlich die Qualität ist das Leben der Patienten. "

URG101 ist eine patentrechtlich geschützte, regionale Therapie bei schmerzhaften Blase / interstitielle Zystitis, die Millionen von Frauen und Männern heimsucht. Urigen hat bereits positive Ergebnisse aus einer Phase-2-Studie von URG101 angekündigt. Die Studie war eine multizentrische, doppelt-blinde, Placebo-kontrollierte Crossover-Studie. Ergebnisse aus der Studie enthalten: Primärer Endpunkt - Verbesserung der durchschnittlichen Daytime Pain (p = 0,03). Sekundäre Endpunkte - Verbesserung der Daytime Dringlichkeit (p = 0,03) und Total Symptom Score (p = 0,03). Darüber hinaus berichteten die Patienten verbesserte Linderung der Symptome mit URG101 wie von Poris gemessen (p = 0,01).
26.04.2010 15:39
Urigen Restructures Debt as Preferred Stock
Urigen Pharmaceuticals, Inc. (OTCBB: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the secured debt held by Platinum-Montaur Life Sciences, LLC has been converted into a newly created Series C Preferred Stock of the Company. As a result of the conversion, the lien on the Company's assets, including its intellectual property will be extinguished.

"This is an important event for Urigen and represents a vote of confidence by our key institutional investor," said Urigen's CEO, William J. Garner, MD.

Michael M. Goldberg, MD, Portfolio Manager, Platinum-Montaur Life Sciences, LLC, and a Director of Urigen, said, "With the filing for the URG101 FDA meeting, I believe that Urigen is making considerable progress and this is a step that we have taken to enhance the profile of the company to attract additional investment."

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. Urigen's URG301, a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. For further information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Urigen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urigen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Urigen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.





Contacts:

Urigen Pharmaceuticals, Inc.
William J. Garner, MD, 415-781-0350
Chief Executive Officer
http://www.urigen.com



© 2010 Business Wire
Antwort auf Beitrag Nr.: 39.380.080 von Zapal am 22.04.10 07:18:25...ich glaub so arg lang dauert's gar nicht mehr,das heute schaut ja schon mal recht vielversprechend aus.
bin schon lange dabei und bleibe auch noch dabei.
Bin davon überzeugt, dass die gute Arbeit leisten.
Das dauert einige Jahre bis so ein Medikament auf den Markt kommt. Und das Geld fließt bei denen auch nicht so üppig, so das es immer wieder zu Verzögerungen kommt.
Meiner Meinung nach dürfte spärestens nächsten Jahr die Phase zwei abgeschlossen sein.
BB
Antwort auf Beitrag Nr.: 39.612.759 von bigblues am 01.06.10 10:14:12Bin erst kurz dabei,obwohl ich's schon lange
beobachte.
Eigentlich dachte ich ja die schließen Phase II
schneller ab und...
Na dann werd ich mich halt doch in Geduld üben müssen :-(


Beitrag zu dieser Diskussion schreiben